Printed From BioPortfolio.com

AstraZeneca admits cancer data for acquired drug was fabricated

04:57 EDT 16 Oct 2017 | Pharmafile

AstraZeneca has revealed that early-stage data concerning the efficacy of its acquired drug acalabrutinib in the treatment of blood cancers and solid tumours was invented and falsified.

AZ acquired the drug when it bought a majority stake in its developer, Acerta Pharma, in 2015 for $4 billion. Currently, AZ is investigating the performance of the drug in more than 25 trials comprising over 2,000 participants.

Original Article: AstraZeneca admits cancer data for acquired drug was fabricated

More From BioPortfolio on "AstraZeneca admits cancer data for acquired drug was fabricated"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches